Stockreport

Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat [Yahoo! Finance]

Sagimet Biosciences Inc.  (SGMT) 
PDF developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the completion of a Phase 1 hepa [Read more]